Oct 14, 2026, 8:00 AM EDT · 3 days ago Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference
2026-09-24T12:21:11.000Z · 23 days ago Tvardi announces publication of preclinical data on STAT3 inhibitor
Sep 24, 2026, 8:00 AM EDT · 23 days ago New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)
Aug 26, 2026, 8:00 AM EDT · 7 weeks ago Tvardi Therapeutics to Participate in Upcoming Investor Events
Aug 14, 2026, 7:00 AM EDT · 2 months ago Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Aug 12, 2026, 8:00 AM EDT · 2 months ago Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
2026-07-30T13:32:04.000Z · 2 months ago Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
Jul 30, 2026, 7:30 AM EDT · 2 months ago Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
2026-07-08T19:40:46.000Z · 3 months ago Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
2026-07-08T19:35:10.000Z · 3 months ago Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
2026-07-08T09:45:22.000Z · 3 months ago Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
2026-07-07T13:10:23.000Z · 3 months ago Tvardi Therapeutics announces positive Phase 1 results for TTI-109
Jul 7, 2026, 7:00 AM EDT · 3 months ago Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
May 8, 2026, 7:00 AM EDT · 5 months ago Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-04-20T09:26:43.000Z · 6 months ago Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
Apr 2, 2026, 8:00 AM EDT · 6 months ago Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-04-01T11:13:02.000Z · 6 months ago Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
2026-04-01T10:34:44.000Z · 6 months ago Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
Mar 31, 2026, 4:01 PM EDT · 6 months ago Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-02-04T11:11:35.000Z · 8 months ago Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Jan 8, 2026, 4:05 PM EST · 9 months ago Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-08T13:25:58.000Z · 9 months ago Tvardi Therapeutics announces further Phase 2 REVERT IPF data
Nov 18, 2025, 8:00 AM EST · 11 months ago Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov 13, 2025, 4:01 PM EST · 11 months ago Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
Nov 4, 2025, 8:00 AM EST · 11 months ago Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Oct 13, 2025, 7:30 AM EDT · 1 year ago Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Aug 21, 2025, 8:00 AM EDT · 1 year ago Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
Aug 14, 2025, 4:01 PM EDT · 1 year ago Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
Jul 15, 2025, 8:00 AM EDT · 1 year ago Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
May 27, 2025, 8:00 AM EDT · 1 year ago Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 20, 2025, 8:00 AM EDT · 1 year ago Tvardi Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2025, 4:05 PM EDT · 1 year ago Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 6, 2025, 7:00 AM EDT · 1 year ago Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
Apr 15, 2025, 4:05 PM EDT · 1 year ago Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics CARA